Oculis to Present Late-Breaking Phase 2 ACUITY Biomarker Analyses of Privosegtor in Optic Neuritis at the 10th Joint ACTRIMS-ECTRIMS Meeting

Impact · against what's priced in

Oculis is expected to see a positive catalyst from the presentation of Phase 2 ACUITY biomarker data for Privosegtor. The focus on NfL and GFAP as indicators of neuroaxonal injury provides translational evidence that may derisk the transition to Phase 3.

Scored by the NIS engine · methodology.

Oculis to Present Late-Breaking Phase 2 ACUITY Biomarker Analyses of Privosegtor in Optic Neuritis at the 10th Joint ACTRIMS-ECTRIMS Meeting

biotech▲13%
healthcare

Oculis to Present Late-Breaking Phase 2 ACUITY Biomarker Analyses of Privosegtor in Optic Neuritis at the 10th Joint ACTRIMS-ECTRIMS Meeting

What matters in this story

Alvotech receives FDA approval for new SIMLANDI® manufacturing process that more than doubles output per batch

Oculis to Present Late-Breaking Phase 2 ACUITY Biomarker Analyses of Privosegtor in Optic Neuritis at the 10th Joint ACTRIMS-ECTRIMS Meeting

What matters in this story

Alvotech receives FDA approval for new SIMLANDI® manufacturing process that more than doubles output per batch

Track these names every morning.

Oracle and AstraZeneca Partner to Advance AI-enabled Healthcare Innovation

Recce Pharmaceuticals advances Phase 3 diabetic foot infection trial to independent data review

CytoDyn Inc. (CYDY) Discusses Latest Scientific, Clinical, Operational, and Financial Progress and Upcoming Priorities Transcript

ARDX Investors Have Opportunity to Lead Ardelyx, Inc. Securities Fraud Lawsuit with SBS Law

Oculis to Present Late-Breaking Phase 2 ACUITY Biomarker Analyses of Privosegtor in Optic Neuritis at the 10th Joint ACTRIMS-ECTRIMS Meeting

What matters in this story

Next reads from the same story arc

Alvotech receives FDA approval for new SIMLANDI® manufacturing process that more than doubles output per batch

Oculis to Present Late-Breaking Phase 2 ACUITY Biomarker Analyses of Privosegtor in Optic Neuritis at the 10th Joint ACTRIMS-ECTRIMS Meeting

What matters in this story

Next reads from the same story arc

Alvotech receives FDA approval for new SIMLANDI® manufacturing process that more than doubles output per batch

Track these names every morning.

Oracle and AstraZeneca Partner to Advance AI-enabled Healthcare Innovation

Recce Pharmaceuticals advances Phase 3 diabetic foot infection trial to independent data review

CytoDyn Inc. (CYDY) Discusses Latest Scientific, Clinical, Operational, and Financial Progress and Upcoming Priorities Transcript

ARDX Investors Have Opportunity to Lead Ardelyx, Inc. Securities Fraud Lawsuit with SBS Law